NEW YORK (GenomeWeb) – Qiagen said today after the close of the market that the National Cancer Center (NCC) of Japan will use the Qiagen Clinical Insight (QCI) bioinformatics platform to analyze, interpret, and report molecular screening of cancer patients to help identify targeted therapies and clinical trial options.
Specifically, Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the NCC, will use the QCI platform to support its molecular profiling services for core and cooperative hospitals of Japan's national precision medicine program.
Qiagen said it has established a data center in Tokyo compliant with Japanese data security and privacy regulations to support this national program.
QCI is a cloud-based clinical decision support software platform used to gain actionable insights from next-generation sequencing data. It features an expert-curated knowledgebase including more than 10 million biomedical findings in addition to QCI-Interpret software, which the company said minimizes the complexity and cost of determining the significance of NGS data.
"The Center for Cancer Genomics and Advanced Therapeutics was established to make a difference by offering cancer patients in Japan the most advanced care available, using genomic medicine to optimize and personalize strategies for treatment and prevention based on somatic and germline profiles," Hiroyuki Mano, director of C-CAT, said in a statement. "C-CAT and our network of hospitals will use the QCI solution because of the breadth and depth of its professionally curated knowledge base, the ability to match patients with approved treatments or clinical trials, and Qiagen's customization of its QCI solution for C-CAT's specific needs."
Financial terms were not disclosed.